Tags

Type your tag names separated by a space and hit enter

Multidrug therapy in leprosy.
J Indian Med Assoc. 2006 Dec; 104(12):686-8.JI

Abstract

Leprosy is an ancient disease, which was treated by local application of chaulmoogra/hydnocarpus oil during prechemotherapeutic era. Since 1940, dapsone was the only chemotherapeutic agent used for treatment of leprosy for about three decades. Prolonged, interrupted and inadequate use of dapsone monotherapy, leads to development of dapsone-resistant cases. Usefulness of clofazimine was known in 1962. Introduction of rifampicin--a powerful bactericidal drug in 1970 has opened the avenues of multidrug therapy to treat leprosy. Multidrug therapy recommended by World Health Organisation came into practice after 1982. The regimen followed now is for duration of 6 months in paucibacillary and for the duration of 12 months in multibacillary cases. It is proven to be safe and effective. Multidrug therapy for leprosy cases is available in the form of blister calender packs and is available free of cost at all government health facilities. Although more new drugs such as ofloxacin, minocyclin, clarithromycin, etc, are known now but they are used as alternative drugs if a component of combination in multidrug therapy becomes contra-indicated. This article brings the details of various drugs used under multidrug therapy, their characteristics, side-effects, regimens and alternative drugs available for treating leprosy.

Authors+Show Affiliations

Netherlands Leprosy Relief, India Branch, New Delhi 110016.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17474286

Citation

Manglani, P R., and M A. Arif. "Multidrug Therapy in Leprosy." Journal of the Indian Medical Association, vol. 104, no. 12, 2006, pp. 686-8.
Manglani PR, Arif MA. Multidrug therapy in leprosy. J Indian Med Assoc. 2006;104(12):686-8.
Manglani, P. R., & Arif, M. A. (2006). Multidrug therapy in leprosy. Journal of the Indian Medical Association, 104(12), 686-8.
Manglani PR, Arif MA. Multidrug Therapy in Leprosy. J Indian Med Assoc. 2006;104(12):686-8. PubMed PMID: 17474286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multidrug therapy in leprosy. AU - Manglani,P R, AU - Arif,M A, PY - 2007/5/4/pubmed PY - 2007/6/7/medline PY - 2007/5/4/entrez SP - 686 EP - 8 JF - Journal of the Indian Medical Association JO - J Indian Med Assoc VL - 104 IS - 12 N2 - Leprosy is an ancient disease, which was treated by local application of chaulmoogra/hydnocarpus oil during prechemotherapeutic era. Since 1940, dapsone was the only chemotherapeutic agent used for treatment of leprosy for about three decades. Prolonged, interrupted and inadequate use of dapsone monotherapy, leads to development of dapsone-resistant cases. Usefulness of clofazimine was known in 1962. Introduction of rifampicin--a powerful bactericidal drug in 1970 has opened the avenues of multidrug therapy to treat leprosy. Multidrug therapy recommended by World Health Organisation came into practice after 1982. The regimen followed now is for duration of 6 months in paucibacillary and for the duration of 12 months in multibacillary cases. It is proven to be safe and effective. Multidrug therapy for leprosy cases is available in the form of blister calender packs and is available free of cost at all government health facilities. Although more new drugs such as ofloxacin, minocyclin, clarithromycin, etc, are known now but they are used as alternative drugs if a component of combination in multidrug therapy becomes contra-indicated. This article brings the details of various drugs used under multidrug therapy, their characteristics, side-effects, regimens and alternative drugs available for treating leprosy. SN - 0019-5847 UR - https://www.unboundmedicine.com/medline/citation/17474286/Multidrug_therapy_in_leprosy_ L2 - https://medlineplus.gov/mycobacterialinfections.html DB - PRIME DP - Unbound Medicine ER -